Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Daniel Lin MD

Daniel W. Lin MD

Professor and Chief of Urologic Oncology, Department of Urology; Pritt Family Endowed Chair in Prostate Cancer Research; Director, Institute for Prostate Cancer Research (IPCR), Department of Urology, University of Washington Seattle, Washington

Dr. Lin is currently Professor and Chief of Urologic Oncology in the Department of Urology and holds the Bridges Endowed Professorship for Prostate Cancer Research at the University of Washington. Dr. Lin received his undergraduate degree from Stanford University and his medical degree from Vanderbilt University before a urology residency at the University of Washington and clinical urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center, followed by an American Foundation for Urologic Disease (AFUD) Physician Scholar Award at the Fred Hutchinson Cancer Research Center.  Dr. Lin’s major basic/translational research interests are in prostate chemoprevention and genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and management of high-risk prostate cancer. Dr. Lin serves on various national committees including the guideline panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA). Dr. Lin receives funding from multiple peer-reviewed grants from the National Cancer Institute (NCI), Department of Defense (DOD), and the Department of Veterans’ Affairs (VA).

Disclosures

Disclosures for Daniel W. Lin, MD

 

Research funding: Genomic Health, Inc., Department of Defense, National Institutes of Health, Canary Foundation

 

Investigator: GenomeDx, Early Detection Research Network/National Cancer Institute,

 

Consultant: Myriad

Recent Contributions to PracticeUpdate:

  1. Adjuvant Radiotherapy in Node Positive Prostate Cancer Patients
  2. 10-Year Disease Progression and Mortality Rates in Men With Biochemical Recurrence vs Persistence After Radical Prostatectomy Who Undergo Salvage Radiation
  3. Deferred Radical Prostatectomy After an Initial Period of Surveillance
  4. Active Surveillance as Initial Management for Newly Diagnosed Prostate Cancer
  5. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification in Men on Active Surveillance
  6. PHI Is Superior to PSA for Predicting Prostate Cancer in Obese Men
  7. Addition of PCA3 Improves Early Detection of Prostate Cancer

Recently Updated